Dose-exposure-response relationships for ceftazidime-avibactam of value to explore dose individualization strategies

Antimicrobial resistance is a pressing global concern rendering traditional treatments ineffective. Ceftazidime, a vital β-lactam antibiotic, faces such challenges, with bacterial strains producing enzymes known as β-lactamases that critically reduce its effectiveness. To counter this, ceftazidime is paired with avibactam, a β-lactamase inhibitor, forming the combination ceftazidime-avibactam (CAZ-AVI). This combination, approved for severe infections involving multidrug-resistant bacteria, presents a crucial solution for conditions like complicated intra-abdominal infection, complicated urinary tract infection, and pneumonia.

The importance of our research lies in understanding the dose-exposure (i.e. pharmacokinetics) and exposure-response (i.e. pharmacodynamics) relationships for CAZ-AVI to explore personalized dosing strategies. Antibiotic resistance demands innovative approaches, and our research aims to impact medical science by contributing evidence for optimizing CAZ-AVI treatment. To conduct this research, we'll use pharmacometrics, a science quantifying drug, disease and clinical trial information to aid efficient drug development. Our focus is on exploring correlations between the pharmacokinetic parameters of ceftazidime and avibactam at the individual level. By developing a joint population pharmacokinetic model, we aim to guide therapeutic drug monitoring, offering insights into whether monitoring both compounds is necessary for optimal dosing.

Our investigation extends to pharmacometric multistate models, exploring time-dependent variables and exposure metrics to predict treatment outcomes. This multistate analysis will consider clinical, microbiological, and safety-related outcomes. Understanding these factors can unveil the intricate dose-exposure-response relationship for CAZ-AVI, aiding in defining exposure targets. By exploring these aspects, we aim to pave the way for personalized treatment strategies, ensuring the effectiveness of CAZ-AVI in eradicating infections while minimizing adverse effects.

In summary, our research on dose-exposure-response relationships for CAZ-AVI is a crucial step toward personalized antibiotic treatment, contributing to fight antimicrobial resistance. Through pharmacometrics and multistate modeling, we hope to better understand how different factors may impact the outcome and clarify the dose-exposure-response for CAZ-AVI, with the ultimate goal to define exposure targets, and integrate important patient factors, to optimally personalize CAZ-AVI treatment to fit the needs of each patient.